25 XP   0   0   10

Elite Pharma Inc
Buy, Hold or Sell?

Let's analyse Elite Pharma Inc together

PenkeI guess you are interested in Elite Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Elite Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Elite Pharma Inc

I send you an email if I find something interesting about Elite Pharma Inc.

Quick analysis of Elite Pharma Inc (30 sec.)










What can you expect buying and holding a share of Elite Pharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.05
Expected worth in 1 year
$0.06
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
$0.02
Return On Investment
12.0%

For what price can you sell your share?

Current Price per Share
$0.13
Expected price per share
$0.13 - $0.16
How sure are you?
50%

1. Valuation of Elite Pharma Inc (5 min.)




Live pricePrice per Share (EOD)

$0.13

Intrinsic Value Per Share

$-0.15 - $-0.03

Total Value Per Share

$-0.10 - $0.02

2. Growth of Elite Pharma Inc (5 min.)




Is Elite Pharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$46.4m$27m$10.6m28.2%

How much money is Elite Pharma Inc making?

Current yearPrevious yearGrowGrow %
Making money$3.8m$1.6m$2.2m58.2%
Net Profit Margin27.1%19.0%--

How much money comes from the company's main activities?

3. Financial Health of Elite Pharma Inc (5 min.)




What can you expect buying and holding a share of Elite Pharma Inc? (5 min.)

Welcome investor! Elite Pharma Inc's management wants to use your money to grow the business. In return you get a share of Elite Pharma Inc.

What can you expect buying and holding a share of Elite Pharma Inc?

First you should know what it really means to hold a share of Elite Pharma Inc. And how you can make/lose money.

Speculation

The Price per Share of Elite Pharma Inc is $0.1335. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Elite Pharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Elite Pharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.05. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Elite Pharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.5%0.003.3%0.001.3%0.001.2%0.00-0.4%
Usd Book Value Change Per Share0.001.0%0.003.0%0.001.4%0.001.2%0.000.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.001.0%0.003.0%0.001.4%0.001.2%0.000.9%
Usd Price Per Share0.14-0.08-0.04-0.06-0.14-
Price to Earnings Ratio50.43-16.89-13.51-8.06--0.73-
Price-to-Total Gains Ratio108.01-31.04-52.72-16.67--19.22-
Price to Book Ratio3.07-1.88-1.43-3.80--0.96-
Price-to-Total Gains Ratio108.01-31.04-52.72-16.67--19.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1335
Number of shares7490
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (7490 shares)29.8812.06
Gains per Year (7490 shares)119.5148.24
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1012011004838
2023923009686
303593500145134
404784700193182
505985900241230
607177100289278
708378300338326
809569500386374
90107610700434422
100119511900482470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%16.04.00.080.0%23.017.00.057.5%34.064.01.034.3%
Book Value Change Per Share3.01.00.075.0%10.02.00.083.3%15.05.00.075.0%24.016.00.060.0%45.054.00.045.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%13.00.086.013.1%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%15.05.00.075.0%24.016.00.060.0%45.054.00.045.5%

Fundamentals of Elite Pharma Inc

About Elite Pharma Inc

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Fundamental data was last updated by Penke on 2024-03-30 19:13:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Elite Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Elite Pharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 4.5% means that $0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Elite Pharma Inc:

  • The MRQ is 4.5%. The company is making a profit. +1
  • The TTM is 27.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ4.5%TTM27.1%-22.6%
TTM27.1%YOY19.0%+8.1%
TTM27.1%5Y4.6%+22.5%
5Y4.6%10Y-175.1%+179.7%
1.1.2. Return on Assets

Shows how efficient Elite Pharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.9% Return on Assets means that Elite Pharma Inc generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Elite Pharma Inc:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 5.4%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM5.4%-4.4%
TTM5.4%YOY3.7%+1.7%
TTM5.4%5Y2.7%+2.6%
5Y2.7%10Y-4.5%+7.3%
1.1.3. Return on Equity

Shows how efficient Elite Pharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Equity means Elite Pharma Inc generated $0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Elite Pharma Inc:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 8.5%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.5%TTM8.5%-7.0%
TTM8.5%YOY5.9%+2.7%
TTM8.5%5Y3.8%+4.7%
5Y3.8%10Y2.3%+1.5%

1.2. Operating Efficiency of Elite Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Elite Pharma Inc is operating .

  • Measures how much profit Elite Pharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Elite Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM4.2%-4.2%
TTM4.2%YOY14.6%-10.3%
TTM4.2%5Y-2.8%+7.0%
5Y-2.8%10Y-77.2%+74.4%
1.2.2. Operating Ratio

Measures how efficient Elite Pharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.32 means that the operating costs are $1.32 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Elite Pharma Inc:

  • The MRQ is 1.320. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.140. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.320TTM1.140+0.179
TTM1.140YOY0.854+0.286
TTM1.1405Y1.067+0.073
5Y1.06710Y1.801-0.735

1.3. Liquidity of Elite Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Elite Pharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.94 means the company has $1.94 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Elite Pharma Inc:

  • The MRQ is 1.939. The company is able to pay all its short-term debts. +1
  • The TTM is 2.195. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.939TTM2.195-0.255
TTM2.195YOY4.189-1.995
TTM2.1955Y2.335-0.141
5Y2.33510Y2.757-0.422
1.3.2. Quick Ratio

Measures if Elite Pharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.84 means the company can pay off $0.84 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Elite Pharma Inc:

  • The MRQ is 0.836. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.011. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.836TTM1.011-0.176
TTM1.011YOY2.985-1.974
TTM1.0115Y1.374-0.363
5Y1.37410Y1.772-0.398

1.4. Solvency of Elite Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Elite Pharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Elite Pharma Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.38 means that Elite Pharma Inc assets are financed with 37.9% credit (debt) and the remaining percentage (100% - 37.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Elite Pharma Inc:

  • The MRQ is 0.379. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.346. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.379TTM0.346+0.032
TTM0.346YOY0.410-0.064
TTM0.3465Y0.432-0.086
5Y0.43210Y0.838-0.406
1.4.2. Debt to Equity Ratio

Measures if Elite Pharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 60.9% means that company has $0.61 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Elite Pharma Inc:

  • The MRQ is 0.609. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.533. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.609TTM0.533+0.076
TTM0.533YOY0.719-0.186
TTM0.5335Y0.821-0.288
5Y0.82110Y0.678+0.143

2. Market Valuation of Elite Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Elite Pharma Inc generates.

  • Above 15 is considered overpriced but always compare Elite Pharma Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 50.43 means the investor is paying $50.43 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Elite Pharma Inc:

  • The EOD is 48.090. Based on the earnings, the company is overpriced. -1
  • The MRQ is 50.431. Based on the earnings, the company is expensive. -2
  • The TTM is 16.891. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD48.090MRQ50.431-2.341
MRQ50.431TTM16.891+33.540
TTM16.891YOY13.506+3.385
TTM16.8915Y8.064+8.827
5Y8.06410Y-0.731+8.795
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Elite Pharma Inc:

  • The EOD is -12.124. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.714. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -27.598. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.124MRQ-12.714+0.590
MRQ-12.714TTM-27.598+14.884
TTM-27.598YOY-7.516-20.082
TTM-27.5985Y69.817-97.415
5Y69.81710Y78.115-8.298
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Elite Pharma Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Elite Pharma Inc:

  • The EOD is 2.927. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.070. Based on the equity, the company is fair priced.
  • The TTM is 1.877. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.927MRQ3.070-0.143
MRQ3.070TTM1.877+1.193
TTM1.877YOY1.428+0.449
TTM1.8775Y3.800-1.923
5Y3.80010Y-0.958+4.757
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Elite Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0010.004-68%0.002-29%0.002-19%0.001+3%
Book Value Per Share--0.0460.037+23%0.027+72%0.021+114%0.009+407%
Current Ratio--1.9392.195-12%4.189-54%2.335-17%2.757-30%
Debt To Asset Ratio--0.3790.346+9%0.410-8%0.432-12%0.838-55%
Debt To Equity Ratio--0.6090.533+14%0.719-15%0.821-26%0.678-10%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0010.004-84%0.002-61%0.002-56%-0.001+177%
Free Cash Flow Per Share---0.003-0.001-70%-0.001-69%0.000-94%-0.001-60%
Free Cash Flow To Equity Per Share---0.003-0.003+7%0.003-207%0.000-3336%0.000-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.026--------
Intrinsic Value_10Y_min---0.148--------
Intrinsic Value_1Y_max---0.001--------
Intrinsic Value_1Y_min---0.006--------
Intrinsic Value_3Y_max---0.005--------
Intrinsic Value_3Y_min---0.026--------
Intrinsic Value_5Y_max---0.010--------
Intrinsic Value_5Y_min---0.054--------
Market Cap135873625.728-5%142489367.86076333540.685+87%38166748.800+273%62410276.255+128%140934540.927+1%
Net Profit Margin--0.0450.271-83%0.190-76%0.046-2%-1.751+3951%
Operating Margin---0.042-100%0.146-100%-0.0280%-0.7720%
Operating Ratio--1.3201.140+16%0.854+54%1.067+24%1.801-27%
Pb Ratio2.927-5%3.0701.877+64%1.428+115%3.800-19%-0.958+131%
Pe Ratio48.090-5%50.43116.891+199%13.506+273%8.064+525%-0.731+101%
Price Per Share0.134-5%0.1400.075+87%0.038+273%0.061+128%0.138+1%
Price To Free Cash Flow Ratio-12.124+5%-12.714-27.598+117%-7.516-41%69.817-118%78.115-116%
Price To Total Gains Ratio102.996-5%108.01031.043+248%52.716+105%16.674+548%-19.225+118%
Quick Ratio--0.8361.011-17%2.985-72%1.374-39%1.772-53%
Return On Assets--0.0090.054-82%0.037-74%0.027-65%-0.045+577%
Return On Equity--0.0150.085-82%0.059-74%0.038-60%0.023-34%
Total Gains Per Share--0.0010.004-68%0.002-29%0.002-19%0.001+3%
Usd Book Value--46413721.00037646374.250+23%27030295.000+72%21695397.550+114%9151677.200+407%
Usd Book Value Change Per Share--0.0010.004-68%0.002-29%0.002-19%0.001+3%
Usd Book Value Per Share--0.0460.037+23%0.027+72%0.021+114%0.009+407%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0010.004-84%0.002-61%0.002-56%-0.001+177%
Usd Free Cash Flow---2801791.000-828768.000-70%-872307.250-69%-161830.100-94%-1134355.950-60%
Usd Free Cash Flow Per Share---0.003-0.001-70%-0.001-69%0.000-94%-0.001-60%
Usd Free Cash Flow To Equity Per Share---0.003-0.003+7%0.003-207%0.000-3336%0.000-100%
Usd Market Cap135873625.728-5%142489367.86076333540.685+87%38166748.800+273%62410276.255+128%140934540.927+1%
Usd Price Per Share0.134-5%0.1400.075+87%0.038+273%0.061+128%0.138+1%
Usd Profit--706354.0003888377.500-82%1625759.000-57%1435520.950-51%-630634.225+189%
Usd Revenue--15538800.00011829406.000+31%8295202.500+87%7490383.050+107%4908414.725+217%
Usd Total Gains Per Share--0.0010.004-68%0.002-29%0.002-19%0.001+3%
 EOD+3 -5MRQTTM+10 -23YOY+11 -225Y+12 -2010Y+21 -11

3.2. Fundamental Score

Let's check the fundamental score of Elite Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1548.090
Price to Book Ratio (EOD)Between0-12.927
Net Profit Margin (MRQ)Greater than00.045
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.836
Current Ratio (MRQ)Greater than11.939
Debt to Asset Ratio (MRQ)Less than10.379
Debt to Equity Ratio (MRQ)Less than10.609
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.009
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Elite Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.400
Ma 20Greater thanMa 500.143
Ma 50Greater thanMa 1000.155
Ma 100Greater thanMa 2000.157
OpenGreater thanClose0.135
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets74,696
Total Liabilities28,283
Total Stockholder Equity46,414
 As reported
Total Liabilities 28,283
Total Stockholder Equity+ 46,414
Total Assets = 74,696

Assets

Total Assets74,696
Total Current Assets37,157
Long-term Assets37,540
Total Current Assets
Cash And Cash Equivalents 5,816
Net Receivables 16,010
Inventory 14,325
Other Current Assets 1,006
Total Current Assets  (as reported)37,157
Total Current Assets  (calculated)37,157
+/-0
Long-term Assets
Property Plant Equipment 10,530
Intangible Assets 6,341
Long-term Assets Other 428
Long-term Assets  (as reported)37,540
Long-term Assets  (calculated)17,299
+/- 20,241

Liabilities & Shareholders' Equity

Total Current Liabilities19,159
Long-term Liabilities9,124
Total Stockholder Equity46,414
Total Current Liabilities
Short Long Term Debt 4,306
Accounts payable 2,891
Total Current Liabilities  (as reported)19,159
Total Current Liabilities  (calculated)7,197
+/- 11,962
Long-term Liabilities
Long term Debt 3,317
Capital Lease Obligations Min Short Term Debt265
Long-term Liabilities  (as reported)9,124
Long-term Liabilities  (calculated)3,581
+/- 5,542
Total Stockholder Equity
Total Stockholder Equity (as reported)46,414
Total Stockholder Equity (calculated)0
+/- 46,414
Other
Capital Stock1,018
Common Stock Shares Outstanding 1,017,781
Net Debt 1,807
Net Invested Capital 54,037
Net Working Capital 17,998
Property Plant and Equipment Gross 26,108



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-30
> Total Assets 
6,600
9,100
8,300
9,162
8,412
24,712
12,746
12,350
12,279
12,782
12,832
12,724
12,019
10,894
9,784
8,696
8,696
6,466
8,824
7,853
6,475
5,325
9,563
9,245
7,899
8,481
8,324
15,702
13,279
11,524
12,044
9,696
22,847
19,598
16,248
15,310
13,267
12,854
11,214
10,920
10,845
10,238
10,902
10,607
10,607
10,865
10,890
11,788
11,490
10,835
10,349
10,312
10,187
10,074
10,371
11,125
10,392
17,412
18,277
24,318
23,968
23,889
25,701
25,920
29,912
28,699
27,131
31,879
33,059
34,870
36,200
34,311
33,888
32,013
32,074
30,883
28,495
27,321
26,377
24,402
24,285
23,533
24,087
24,957
27,822
27,606
28,665
26,189
29,993
30,624
31,947
35,149
48,108
50,343
52,716
40,896
46,499
70,719
74,696
74,69670,71946,49940,89652,71650,34348,10835,14931,94730,62429,99326,18928,66527,60627,82224,95724,08723,53324,28524,40226,37727,32128,49530,88332,07432,01333,88834,31136,20034,87033,05931,87927,13128,69929,91225,92025,70123,88923,96824,31818,27717,41210,39211,12510,37110,07410,18710,31210,34910,83511,49011,78810,89010,86510,60710,60710,90210,23810,84510,92011,21412,85413,26715,31016,24819,59822,8479,69612,04411,52413,27915,7028,3248,4817,8999,2459,5635,3256,4757,8538,8246,4668,6968,6969,78410,89412,01912,72412,83212,78212,27912,35012,74624,7128,4129,1628,3009,1006,600
   > Total Current Assets 
4,800
4,700
4,100
4,848
4,009
20,293
8,229
7,779
7,766
8,226
8,409
7,837
7,162
5,881
4,666
0
3,500
1,449
3,883
2,600
1,345
480
4,736
4,504
3,203
3,496
3,347
10,564
8,235
6,425
6,588
3,410
16,133
12,449
7,101
6,153
4,177
3,877
2,394
2,319
2,346
2,114
2,738
0
2,486
2,467
2,399
3,147
2,673
2,078
1,542
1,498
1,420
1,364
1,642
2,543
1,785
3,279
3,918
9,925
12,082
11,711
13,186
12,331
15,785
14,095
12,421
16,714
17,987
19,663
20,621
18,413
16,436
14,611
14,764
13,702
11,458
10,378
9,431
8,857
8,532
8,116
9,042
10,251
13,251
13,275
14,538
12,195
15,317
15,882
17,475
18,861
31,870
30,473
33,165
21,510
27,445
34,729
37,157
37,15734,72927,44521,51033,16530,47331,87018,86117,47515,88215,31712,19514,53813,27513,25110,2519,0428,1168,5328,8579,43110,37811,45813,70214,76414,61116,43618,41320,62119,66317,98716,71412,42114,09515,78512,33113,18611,71112,0829,9253,9183,2791,7852,5431,6421,3641,4201,4981,5422,0782,6733,1472,3992,4672,48602,7382,1142,3462,3192,3943,8774,1776,1537,10112,44916,1333,4106,5886,4258,23510,5643,3473,4963,2034,5044,7364801,3452,6003,8831,4493,50004,6665,8817,1627,8378,4098,2267,7667,7798,22920,2934,0094,8484,1004,7004,800
       Cash And Cash Equivalents 
4,700
4,700
4,100
3,937
3,587
2,973
7,855
7,297
7,027
7,865
7,744
6,852
6,628
5,652
4,499
0
3,264
1,373
3,685
2,105
804
154
4,565
3,902
2,693
1,856
1,648
8,919
6,700
4,896
5,085
2,045
14,441
10,989
5,943
3,703
1,687
1,531
336
283
763
180
867
578
578
594
415
1,826
1,759
1,339
569
668
475
207
66
369
231
766
1,081
6,942
8,173
7,627
8,274
7,464
11,617
9,031
8,103
11,512
12,815
12,580
13,283
10,595
9,573
7,557
7,244
7,179
5,644
4,705
3,681
2,278
2,577
2,256
1,870
1,132
2,788
4,366
5,413
3,193
4,751
4,491
7,288
8,535
19,780
18,555
17,909
7,832
9,077
8,654
5,816
5,8168,6549,0777,83217,90918,55519,7808,5357,2884,4914,7513,1935,4134,3662,7881,1321,8702,2562,5772,2783,6814,7055,6447,1797,2447,5579,57310,59513,28312,58012,81511,5128,1039,03111,6177,4648,2747,6278,1736,9421,081766231369662074756685691,3391,7591,8264155945785788671807632833361,5311,6873,7035,94310,98914,4412,0455,0854,8966,7008,9191,6481,8562,6933,9024,5651548042,1053,6851,3733,26404,4995,6526,6286,8527,7447,8657,0277,2977,8552,9733,5873,9374,1004,7004,700
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000010000000000000
       Net Receivables 
0
0
0
0
0
0
8
94
407
134
379
40
30
110
0
0
5
0
0
153
153
153
0
142
0
0
0
0
0
136
120
216
213
0
0
148
303
405
163
1
0
357
413
0
405
441
626
572
514
253
483
397
498
563
526
665
499
636
1,024
732
1,167
1,098
1,714
1,446
1,049
1,416
747
1,530
1,220
1,146
545
934
721
1,085
1,161
676
1,062
1,016
660
1,322
999
2,030
2,565
4,107
4,370
4,076
3,296
3,496
3,378
4,672
2,661
3,058
3,965
4,230
5,546
3,095
6,201
10,495
16,010
16,01010,4956,2013,0955,5464,2303,9653,0582,6614,6723,3783,4963,2964,0764,3704,1072,5652,0309991,3226601,0161,0626761,1611,0857219345451,1461,2201,5307471,4161,0491,4461,7141,0981,1677321,02463649966552656349839748325351457262644140504133570116340530314800213216120136000001420153153153005001103040379134407948000000
       Other Current Assets 
100
0
0
910
422
17,319
366
82
332
77
50
525
251
89
167
132
231
76
198
342
388
173
171
460
509
1,640
1,699
1,645
1,534
1,394
1,383
1,149
1,480
1,460
1,158
178
285
227
153
332
144
122
62
132
132
101
55
133
88
105
59
128
84
113
66
151
116
157
281
318
216
463
334
388
257
295
389
378
216
302
765
468
251
260
1,059
949
611
171
898
741
416
98
796
870
527
371
1,027
493
485
174
831
527
508
220
1,108
1,033
998
356
1,006
1,0063569981,0331,1082205085278311744854931,027371527870796984167418981716119491,0592602514687653022163783892952573883344632163182811571161516611384128591058813355101132132621221443321532272851781,1581,4601,4801,1491,3831,3941,5341,6451,6991,640509460171173388342198762311321678925152550773328236617,31942291000100
   > Long-term Assets 
1,800
4,400
4,200
4,315
4,403
4,419
4,517
4,572
4,513
4,556
4,423
4,887
4,857
5,013
5,118
0
5,196
5,017
4,941
5,253
5,130
4,845
4,826
4,741
4,697
4,985
4,977
5,138
5,045
5,099
5,456
6,286
6,714
7,149
9,147
9,157
9,090
8,977
8,820
8,601
8,500
8,124
8,164
0
8,121
8,398
8,492
8,641
8,818
8,756
8,807
8,814
8,767
8,710
8,729
8,582
8,607
14,133
14,359
14,393
11,887
12,178
12,516
13,590
14,127
14,603
14,710
15,165
15,072
15,207
15,578
15,898
17,452
17,402
17,310
17,180
17,038
16,943
16,946
15,545
15,753
15,417
15,044
14,705
14,571
14,331
14,127
13,995
14,676
14,742
14,472
16,288
16,238
19,871
19,551
19,386
19,055
35,990
37,540
37,54035,99019,05519,38619,55119,87116,23816,28814,47214,74214,67613,99514,12714,33114,57114,70515,04415,41715,75315,54516,94616,94317,03817,18017,31017,40217,45215,89815,57815,20715,07215,16514,71014,60314,12713,59012,51612,17811,88714,39314,35914,1338,6078,5828,7298,7108,7678,8148,8078,7568,8188,6418,4928,3988,12108,1648,1248,5008,6018,8208,9779,0909,1579,1477,1496,7146,2865,4565,0995,0455,1384,9774,9854,6974,7414,8264,8455,1305,2534,9415,0175,19605,1185,0134,8574,8874,4234,5564,5134,5724,5174,4194,4034,3154,2004,4001,800
       Property Plant Equipment 
1,600
1,900
2,400
2,479
2,571
2,590
2,546
3,891
3,838
3,810
3,762
3,866
3,891
3,921
4,339
4,390
4,391
4,229
4,148
4,090
3,994
4,283
4,274
4,194
4,152
4,139
4,139
4,309
4,224
4,281
4,647
5,454
5,788
6,342
5,003
5,009
4,945
4,835
4,682
4,575
4,455
4,335
4,216
4,096
4,096
3,910
3,946
4,118
4,232
4,244
4,235
4,285
4,185
4,172
4,109
4,029
3,958
3,940
4,117
4,200
4,945
5,167
5,485
6,402
6,954
7,555
7,656
8,111
8,223
8,352
8,719
9,039
9,321
9,267
9,133
8,994
8,872
8,755
8,755
8,444
8,647
8,306
7,931
7,591
7,456
7,156
6,996
6,864
7,545
7,339
7,068
6,985
6,736
10,568
10,249
10,439
10,105
9,772
10,530
10,5309,77210,10510,43910,24910,5686,7366,9857,0687,3397,5456,8646,9967,1567,4567,5917,9318,3068,6478,4448,7558,7558,8728,9949,1339,2679,3219,0398,7198,3528,2238,1117,6567,5556,9546,4025,4855,1674,9454,2004,1173,9403,9584,0294,1094,1724,1854,2854,2354,2444,2324,1183,9463,9104,0964,0964,2164,3354,4554,5754,6824,8354,9455,0095,0036,3425,7885,4544,6474,2814,2244,3094,1394,1394,1524,1944,2744,2833,9944,0904,1484,2294,3914,3904,3393,9213,8913,8663,7623,8103,8383,8912,5462,5902,5712,4792,4001,9001,600
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,329
3,329
0
0
0
0
0
0
0
0
3,329
3,329
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000003,3293,329000000003,3293,329000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
30
29
28
28
57
56
55
54
55
66
72
75
105
105
94
109
102
96
90
84
81
76
70
65
59
54
54
48
43
41
39
37
35
33
32
30
28
26
24
22
96
96
555
563
598
608
614
630
643
659
666
683
694
713
6,314
6,315
6,350
6,357
6,358
6,363
6,382
6,388
6,400
6,408
6,412
6,412
6,418
6,419
6,419
7,680
7,694
7,705
7,713
7,713
7,713
7,713
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,634
6,341
6,341
6,341
6,341
6,3416,3416,3416,3416,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6346,6347,7137,7137,7137,7137,7057,6947,6806,4196,4196,4186,4126,4126,4086,4006,3886,3826,3636,3586,3576,3506,3156,3147136946836666596436306146085985635559696222426283032333537394143485454596570768184909610210994105105757266555455565728282930000
       Long-term Assets Other 
200
2,500
1,800
1,806
1,803
1,801
1,943
623
620
691
608
967
900
1,020
704
0
701
694
684
1,061
1,040
472
469
465
469
776
773
770
767
764
761
789
885
768
4,106
4,113
4,112
4,111
779
668
689
425
587
0
599
603
654
595
649
569
613
557
594
542
594
515
592
535
563
498
585
652
668
806
785
649
646
642
438
438
440
440
452
441
473
473
453
475
478
468
472
477
479
480
481
541
497
497
497
770
770
497
697
497
497
412
415
423
428
42842341541249749769749777077049749749754148148047947747246847847545347347344145244044043843864264664978580666865258549856353559251559454259455761356964959565460359905874256896687794,1114,1124,1134,1067688857897617647677707737764694654694721,0401,06168469470107041,0209009676086916206231,9431,8011,8031,8061,8002,500200
> Total Liabilities 
100
3,200
3,100
3,598
3,198
15,019
2,997
3,170
3,407
2,942
4,150
4,571
4,312
4,108
3,066
3,269
3,270
3,380
3,295
3,805
3,637
3,664
3,275
3,543
3,182
5,198
5,358
5,929
5,307
5,348
5,490
6,186
8,709
5,689
4,750
4,761
4,658
4,721
4,522
4,977
14,437
17,157
26,743
21,205
21,205
23,672
17,459
29,659
50,332
34,523
24,660
25,295
33,545
31,875
22,727
19,799
16,792
23,264
23,204
105,516
108,418
79,252
56,241
60,651
45,235
16,206
29,200
20,715
17,523
12,395
10,153
8,647
16,204
11,918
12,180
12,407
11,503
11,648
12,738
13,006
12,243
12,688
15,007
14,301
16,033
12,989
12,035
10,038
11,291
10,122
9,157
9,927
22,575
23,152
22,542
11,936
16,382
25,625
28,283
28,28325,62516,38211,93622,54223,15222,5759,9279,15710,12211,29110,03812,03512,98916,03314,30115,00712,68812,24313,00612,73811,64811,50312,40712,18011,91816,2048,64710,15312,39517,52320,71529,20016,20645,23560,65156,24179,252108,418105,51623,20423,26416,79219,79922,72731,87533,54525,29524,66034,52350,33229,65917,45923,67221,20521,20526,74317,15714,4374,9774,5224,7214,6584,7614,7505,6898,7096,1865,4905,3485,3075,9295,3585,1983,1823,5433,2753,6643,6373,8053,2953,3803,2703,2693,0664,1084,3124,5714,1502,9423,4073,1702,99715,0193,1983,5983,1003,200100
   > Total Current Liabilities 
100
300
200
713
313
12,254
232
405
642
307
662
782
543
509
327
550
550
847
782
1,310
1,161
1,230
890
1,176
850
1,218
1,378
1,949
1,327
1,553
1,695
2,391
4,914
2,094
1,110
1,124
1,023
1,298
1,103
1,560
1,679
1,739
1,917
4,761
4,761
5,046
5,051
4,669
4,626
4,474
4,722
4,549
4,763
4,762
5,383
5,357
5,310
11,724
12,505
6,161
7,312
3,806
4,355
5,069
3,365
4,508
5,364
4,654
4,379
5,135
4,681
3,345
3,514
3,649
4,743
5,115
4,671
5,364
6,940
6,906
7,611
7,169
7,746
8,640
8,635
7,011
7,242
5,813
6,795
6,304
5,878
6,694
7,080
6,843
6,654
7,834
12,077
19,078
19,159
19,15919,07812,0777,8346,6546,8437,0806,6945,8786,3046,7955,8137,2427,0118,6358,6407,7467,1697,6116,9066,9405,3644,6715,1154,7433,6493,5143,3454,6815,1354,3794,6545,3644,5083,3655,0694,3553,8067,3126,16112,50511,7245,3105,3575,3834,7624,7634,5494,7224,4744,6264,6695,0515,0464,7614,7611,9171,7391,6791,5601,1031,2981,0231,1241,1102,0944,9142,3911,6951,5531,3271,9491,3781,2188501,1768901,2301,1611,31078284755055032750954378266230764240523212,254313713200300100
       Short-term Debt 
0
0
100
115
115
120
120
120
120
130
130
205
205
215
215
0
215
225
225
225
225
284
295
293
297
175
175
175
175
185
185
185
3,185
200
210
210
210
220
220
221
288
318
260
0
3,467
12
13
13
14
14
3,395
13
10
207
3,892
3,991
3,990
9,769
9,773
3,933
4,092
1,110
1,130
1,058
857
884
1,313
1,281
511
412
510
487
417
439
500
655
622
548
587
654
735
652
1,851
2,061
1,983
1,899
1,923
599
789
721
554
557
642
528
493
326
4,260
0
0
004,2603264935286425575547217895991,9231,8991,9832,0611,8516527356545875486226555004394174875104125111,2811,3138848571,0581,1301,1104,0923,9339,7739,7693,9903,9913,89220710133,39514141313123,46702603182882212202202102102102003,185185185185175175175175297293295284225225225225215021521520520513013012012012012011511510000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,281
511
412
510
487
3,882
439
500
655
622
548
587
654
540
452
1,647
1,852
1,771
1,682
1,702
411
583
511
400
354
435
503
471
311
4,251
4,295
4,306
4,3064,2954,2513114715034353544005115834111,7021,6821,7711,8521,6474525406545875486226555004393,8824875104125111,2810000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
100
200
0
598
198
119
106
220
147
70
103
142
100
234
112
335
335
622
557
1,085
786
946
595
883
553
1,043
1,203
1,740
1,152
1,368
1,510
2,206
1,729
1,894
798
850
750
1,041
683
981
1,056
1,086
1,306
987
987
4,727
4,600
4,603
4,456
4,322
1,227
4,451
4,696
4,513
1,401
1,325
1,284
1,925
1,991
2,215
3,823
2,682
3,878
4,581
2,906
4,023
3,756
1,804
1,458
2,280
1,355
1,050
881
860
1,444
1,658
1,065
1,141
2,309
1,375
2,086
1,730
986
1,578
2,074
589
701
930
2,052
1,790
1,284
1,431
1,614
1,724
1,472
2,447
1,875
3,609
2,891
2,8913,6091,8752,4471,4721,7241,6141,4311,2841,7902,0529307015892,0741,5789861,7302,0861,3752,3091,1411,0651,6581,4448608811,0501,3552,2801,4581,8043,7564,0232,9064,5813,8782,6823,8232,2151,9911,9251,2841,3251,4014,5134,6964,4511,2274,3224,4564,6034,6004,7279879871,3061,0861,0569816831,0417508507981,8941,7292,2061,5101,3681,1521,7401,2031,0435538835959467861,085557622335335112234100142103701472201061191985980200100
       Other Current Liabilities 
0
100
100
0
0
12,015
6
65
126
107
328
436
238
60
0
0
0
0
0
0
150
0
0
0
0
0
0
33
0
0
0
0
0
2,094
102
63
63
37
882
1,340
335
335
350
307
306
108
399
39
143
124
86
71
44
29
28
28
24
16
728
32
3,206
0
3,212
3,998
2,495
3,611
3,038
555
1,397
1,430
1,802
795
1,202
1,337
1,786
1,789
1,970
2,662
3,031
3,714
3,635
4,051
4,424
4,821
4,565
4,509
4,605
4,271
3,941
3,779
4,026
4,693
4,810
4,578
4,676
5,048
5,929
0
0
005,9295,0484,6764,5784,8104,6934,0263,7793,9414,2714,6054,5094,5654,8214,4244,0513,6353,7143,0312,6621,9701,7891,7861,3371,2027951,8021,4301,3975553,0383,6112,4953,9983,21203,206327281624282829447186124143393991083063073503353351,3408823763631022,09400000330000001500000006023843632810712665612,015001001000
   > Long-term Liabilities 
100
2,900
2,900
2,885
2,885
2,765
2,765
2,765
2,765
2,635
3,488
3,788
3,769
3,599
2,739
0
2,720
2,533
2,514
2,495
2,476
2,433
2,385
2,367
2,332
3,980
3,980
3,980
3,980
3,795
3,795
3,795
3,795
3,595
3,640
3,637
3,635
3,422
3,420
3,417
12,757
15,418
24,826
0
16,444
18,626
12,408
24,990
45,707
30,049
19,937
20,746
28,782
27,113
17,344
14,441
11,482
11,541
10,699
99,355
101,106
75,446
51,886
55,582
41,870
11,698
23,836
16,061
13,144
7,260
5,472
5,302
12,690
8,269
7,437
7,292
6,832
6,283
5,798
6,100
4,631
5,519
7,260
5,661
7,398
5,978
4,792
4,225
4,496
3,818
3,279
3,233
15,495
16,309
15,887
4,102
4,305
6,547
9,124
9,1246,5474,3054,10215,88716,30915,4953,2333,2793,8184,4964,2254,7925,9787,3985,6617,2605,5194,6316,1005,7986,2836,8327,2927,4378,26912,6905,3025,4727,26013,14416,06123,83611,69841,87055,58251,88675,446101,10699,35510,69911,54111,48214,44117,34427,11328,78220,74619,93730,04945,70724,99012,40818,62616,444024,82615,41812,7573,4173,4203,4223,6353,6373,6403,5953,7953,7953,7953,7953,9803,9803,9803,9802,3322,3672,3852,4332,4762,4952,5142,5332,72002,7393,5993,7693,7883,4882,6352,7652,7652,7652,7652,8852,8852,9002,900100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
0
0
0
0
0
0
0
0
0
0
0
0
2,065
2,065
2,065
2,065
1,845
1,845
0
0
0
0
0
0
0
0
0
2,176
2,052
2,199
2,127
2,038
0
1,863
1,800
2,936
2,792
2,745
1,741
1,664
0
0
0
0
0
0
0
3,578
0
0
003,57800000001,6641,7412,7452,7922,9361,8001,86302,0382,1272,1992,0522,1760000000001,8451,8452,0652,0652,0652,06500000000000075000000000000000000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,571
32,857
58,429
0
46,429
0
0
0
13,904
13,904
13,904
13,904
13,904
13,904
13,904
13,904
13,904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000013,90413,90413,90413,90413,90413,90413,90413,90413,90400046,429058,42932,85728,5710000000000000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
853
853
841
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,344
12,232
21,643
16,424
20,675
18,570
12,332
24,983
45,706
30,049
19,937
20,741
28,782
27,113
17,344
14,441
11,482
11,540
10,699
99,267
101,105
73,381
49,820
52,957
15,149
13,520
21,991
13,696
11,036
5,280
3,449
3,140
9,225
4,953
4,096
3,961
3,455
3,031
2,399
2,773
1,069
2,119
5,176
3,694
4,350
3,130
2,047
2,445
1,828
1,406
913
1,008
1,506
774
398
0
727
0
0
0072703987741,5061,0089131,4061,8282,4452,0473,1304,3503,6945,1762,1191,0692,7732,3993,0313,4553,9614,0964,9539,2253,1403,4495,28011,03613,69621,99113,52015,14952,95749,82073,381101,10599,26710,69911,54011,48214,44117,34427,11328,78220,74119,93730,04945,70624,98312,33218,57020,67516,42421,64312,2329,3440000000000000000000000000084185385300000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
176
172
0
0
0
0
0
0
0
0
142
139
136
132
129
126
14,587
12,970
21,383
3,279
3,026
2,772
2,519
2,266
7,247
7,247
7,247
7,247
999
746
492
239
6,168
6,168
6,168
6,168
6,168
56
56
46
1,790
6,168
6,168
6,168
6,168
6,168
6,168
0
711
0
0
0071106,1686,1686,1686,1686,1686,1681,7904656566,1686,1686,1686,1686,1682394927469997,2477,2477,2477,2472,2662,5192,7723,0263,27921,38312,97014,58712612913213613914200000000172176000000000000000000000000000000000000000000000000
> Total Stockholder Equity
6,500
5,900
5,200
5,565
5,213
9,693
9,749
9,180
8,872
9,840
8,683
8,154
7,707
6,786
6,718
5,427
5,427
3,086
5,529
4,048
2,838
1,661
6,288
5,702
4,717
3,283
2,965
9,774
7,973
6,177
6,549
3,511
14,138
13,909
11,498
10,549
8,609
8,133
6,692
5,943
-3,591
-6,919
-15,841
0
-10,598
-12,807
-6,569
-17,871
-38,842
-23,688
-14,310
-14,984
-23,358
-21,801
-12,356
-8,673
-6,400
-5,852
-4,927
-81,198
-84,449
-55,363
-30,539
-34,731
-15,323
12,493
-2,069
11,163
15,536
22,475
26,047
25,664
17,684
20,094
19,894
18,476
16,992
15,674
13,639
11,396
12,042
10,846
9,080
10,656
11,789
14,617
16,631
16,152
18,701
20,503
22,790
25,222
25,533
27,191
30,175
28,960
30,117
45,094
46,414
46,41445,09430,11728,96030,17527,19125,53325,22222,79020,50318,70116,15216,63114,61711,78910,6569,08010,84612,04211,39613,63915,67416,99218,47619,89420,09417,68425,66426,04722,47515,53611,163-2,06912,493-15,323-34,731-30,539-55,363-84,449-81,198-4,927-5,852-6,400-8,673-12,356-21,801-23,358-14,984-14,310-23,688-38,842-17,871-6,569-12,807-10,5980-15,841-6,919-3,5915,9436,6928,1338,60910,54911,49813,90914,1383,5116,5496,1777,9739,7742,9653,2834,7175,7026,2881,6612,8384,0485,5293,0865,4275,4276,7186,7867,7078,1548,6839,8408,8729,1809,7499,6935,2135,5655,2005,9006,500
   Common Stock
100
100
100
89
89
89
94
94
94
96
96
97
97
98
105
105
105
106
122
122
122
122
131
180
181
183
193
192
194
196
207
208
210
220
226
231
243
294
351
608
700
745
80
84
84
93
98
181
243
255
265
332
346
350
350
374
396
495
513
560
568
592
609
631
660
682
688
712
731
894
911
928
781
786
789
803
805
817
821
825
829
833
834
841
841
1,009
1,009
1,009
1,011
1,011
1,011
1,011
1,011
1,014
1,014
1,014
1,014
0
0
001,0141,0141,0141,0141,0111,0111,0111,0111,0111,0091,0091,00984184183483382982582181780580378978678192891189473171268868266063160959256856051349539637435035034633226525524318198938484807457006083512942432312262202102082071961941921931831811801311221221221221061051051059897979696949494898989100100100
   Retained Earnings -119,715-120,421-135,356-136,498-135,269-138,239-139,754-140,060-142,488-144,772-146,569-148,958-148,475-150,487-152,969-154,046-154,983-153,122-151,526-151,806-149,142-146,798-144,215-142,527-139,697-139,207-141,022-138,854-135,663-137,333-141,571-142,665-151,164-136,943-179,999-196,077-187,012-208,029-229,408-225,007-138,209-137,147-127,510-128,431-130,028-139,391-140,441-129,919-122,914-131,675-145,594-114,861-98,256-104,184-101,2790-106,029-96,438-92,766-90,002-88,906-86,825-84,029-81,190-79,266-75,844-68,263-62,811-58,564-54,801-52,518-50,217-45,826-44,124-42,404-41,177-39,830-38,470-36,942-35,105-33,554-32,185-28,5910-27,416-25,364-24,395-23,628-22,059-21,719-21,447-21,000-20,384-20,191-7,625-7,035-6,200-5,500-4,800
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
106,816
108,039
0
0
0
0
0
0
0
0
133,075
143,555
144,698
152,381
156,170
161,022
116,657
113,525
90,285
0
110,254
159,221
161,105
163,896
144,328
144,918
145,206
146,603
146,805
148,058
148,364
148,780
149,143
0
149,632
150,265
150,320
164,402
164,404
164,407
164,566
0
0
0
0
0
0
0
164,766
0
0
00164,7660000000164,566164,407164,404164,402150,320150,265149,6320149,143148,780148,364148,058146,805146,603145,206144,918144,328163,896161,105159,221110,254090,285113,525116,657161,022156,170152,381144,698143,555133,07500000000108,039106,816000000000000000000000000000000000000000000000000
   Treasury Stock00-3070000000-307-307-307-307-307-307-3070-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-307-27000000000000000
   Other Stockholders Equity 
11,200
11,300
11,300
12,511
12,749
12,780
18,024
18,072
18,210
19,248
19,284
19,469
19,535
20,121
34,601
0
35,012
36,266
40,061
40,432
41,059
41,409
47,383
48,422
48,662
48,948
50,322
61,855
62,353
62,838
66,963
66,189
82,266
89,608
90,612
91,583
92,470
94,739
95,247
98,697
88,474
88,775
93,828
0
94,437
95,239
95,661
100,999
110,820
112,160
112,882
119,264
121,512
122,129
122,301
124,452
125,888
136,084
138,160
148,757
150,105
158,009
162,008
166,789
170,249
122,290
96,534
115,557
116,846
165,979
168,030
171,016
151,633
152,449
153,022
154,705
155,208
156,773
157,397
158,125
158,815
159,538
159,959
160,915
161,238
175,641
164,097
164,101
164,259
164,263
164,267
164,270
164,276
164,416
164,429
164,444
164,459
0
0
00164,459164,444164,429164,416164,276164,270164,267164,263164,259164,101164,097175,641161,238160,915159,959159,538158,815158,125157,397156,773155,208154,705153,022152,449151,633171,016168,030165,979116,846115,55796,534122,290170,249166,789162,008158,009150,105148,757138,160136,084125,888124,452122,301122,129121,512119,264112,882112,160110,820100,99995,66195,23994,437093,82888,77588,47498,69795,24794,73992,47091,58390,61289,60882,26666,18966,96362,83862,35361,85550,32248,94848,66248,42247,38341,40941,05940,43240,06136,26635,012034,60120,12119,53519,46919,28419,24818,21018,07218,02412,78012,74912,51111,30011,30011,200



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue34,155,114
Cost of Revenue-17,561,093
Gross Profit16,594,02116,594,021
 
Operating Income (+$)
Gross Profit16,594,021
Operating Expense-12,918,019
Operating Income2,025,1113,676,002
 
Operating Expense (+$)
Research Development6,200,163
Selling General Administrative5,122,272
Selling And Marketing Expenses0
Operating Expense12,918,01911,322,435
 
Net Interest Income (+$)
Interest Income7
Interest Expense-1,112,707
Other Finance Cost-1,111,594
Net Interest Income-1,105
 
Pretax Income (+$)
Operating Income2,025,111
Net Interest Income-1,105
Other Non-Operating Income Expenses0
Income Before Tax (EBT)3,985,87464,348
EBIT - interestExpense = 912,404
3,985,874
5,522,609
Interest Expense1,112,707
Earnings Before Interest and Taxes (EBIT)2,025,1115,098,581
Earnings Before Interest and Taxes (EBITDA)3,288,563
 
After tax Income (+$)
Income Before Tax3,985,874
Tax Provision-424
Net Income From Continuing Ops3,5623,985,450
Net Income4,409,902
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses30,479,112
Total Other Income/Expenses Net1,960,7631,105
 

Technical Analysis of Elite Pharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Elite Pharma Inc. The general trend of Elite Pharma Inc is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Elite Pharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Elite Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.16 < 0.16 < 0.16.

The bearish price targets are: 0.13 > 0.13 > 0.13.

Tweet this
Elite Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Elite Pharma Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Elite Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Elite Pharma Inc. The current macd is -0.00505774.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Elite Pharma Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Elite Pharma Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Elite Pharma Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Elite Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartElite Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Elite Pharma Inc. The current adx is 22.08.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Elite Pharma Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Elite Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Elite Pharma Inc. The current sar is 0.15451218.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Elite Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Elite Pharma Inc. The current rsi is 32.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Elite Pharma Inc Daily Relative Strength Index (RSI) ChartElite Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Elite Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Elite Pharma Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Elite Pharma Inc Daily Stochastic Oscillator ChartElite Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Elite Pharma Inc. The current cci is -85.65409178.

Elite Pharma Inc Daily Commodity Channel Index (CCI) ChartElite Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Elite Pharma Inc. The current cmo is -49.82788777.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Elite Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartElite Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Elite Pharma Inc. The current willr is -88.33333333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Elite Pharma Inc Daily Williams %R ChartElite Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Elite Pharma Inc.

Elite Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Elite Pharma Inc. The current atr is 0.00963976.

Elite Pharma Inc Daily Average True Range (ATR) ChartElite Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Elite Pharma Inc. The current obv is 26,780,938.

Elite Pharma Inc Daily On-Balance Volume (OBV) ChartElite Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Elite Pharma Inc. The current mfi is 29.66.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Elite Pharma Inc Daily Money Flow Index (MFI) ChartElite Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Elite Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-03MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Elite Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Elite Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.400
Ma 20Greater thanMa 500.143
Ma 50Greater thanMa 1000.155
Ma 100Greater thanMa 2000.157
OpenGreater thanClose0.135
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Elite Pharma Inc with someone you think should read this too:
  • Are you bullish or bearish on Elite Pharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Elite Pharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Elite Pharma Inc

I send you an email if I find something interesting about Elite Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Elite Pharma Inc.

Receive notifications about Elite Pharma Inc in your mailbox!